Highlights

  • Mayne Pharma Group Limited (ASX:MYX) recorded FY26 revenue of AUD 383.7 million, down 6%.
  • FY26 underlying EBITDA declined 27% to AUD 34.2 million, while gross margin reached 64.7%.
  • The company launched its US prescription distribution platform, DistributeRx, in March 2026.
  • October ASX updates addressed Cosette-related litigation and IMVEXXY patent proceedings.

Mayne Pharma Group Limited (ASX:MYX), an Australian-listed specialty pharmaceutical company with extensive US operations, enters its 2027 financial year following changes to its product distribution model and a complex period of legal proceedings. At the time of writing this article on 19 October 2026, the shares were indicated at AUD 2.59, up 2.78% during the day’s trading session. The company’s FY26 report and October announcements provide a picture of how its branded medicines, cash position and ongoing disputes may shape near-term reporting priorities.

Company Business

Mayne Pharma markets specialty pharmaceuticals with an emphasis on Women’s Health and Dermatology, alongside an International division. Its portfolio includes NEXTSTELLIS, BIJUVA, IMVEXXY and ANNOVERA in women’s health, and dermatology brands including TWYNEO, EPSOLAY and RHOFADE. The company also manufactures pharmaceuticals at Salisbury in South Australia, where a facility upgrade was completed during FY26.

The US is central to the group’s commercial activity. Distribution arrangements, reimbursement terms, prescribing activity and product exclusivity affect realised sales. In March 2026, the company introduced DistributeRx, a direct-to-patient prescription distribution business using digital processes and pharmacy fulfilment. The platform also offers distribution services to third-party pharmaceutical manufacturers, extending the group’s business beyond its own products.

Recent Development

In mid-October 2026, Mayne Pharma published an announcement concerning a court decision in proceedings involving Cosette Pharmaceuticals. The dispute followed a previously proposed acquisition transaction that did not proceed as planned. The company had reported receiving AUD 14.4 million in court-ordered legal costs and interest from Cosette in June 2026. Separate claims for damages and associated proceedings have also featured in the company’s disclosures.

An announcement on 16 October addressed settlement of US patent litigation involving IMVEXXY and Teva USA. This followed a late-September announcement about IMVEXXY patent proceedings involving Sun Pharma and an early-October update on post-marketing study requirements. Together, the announcements make patent protection, regulatory obligations and resolution of disputes significant subjects for subsequent company reporting. The financial implications of individual settlements should not be assumed where terms have not been publicly established.

Beyond legal matters, Mayne Pharma launched DistributeRx in March and disclosed that 5,042 unique prescribers had joined the platform by its FY26 reporting date. In May, it announced plans to expand Adelaide Apothecary’s fulfilment operations into a larger automated facility in Lexington, Kentucky. The company expected the facility to commence operations in early 2027.

Financial Performance and Sector Context

For the financial year ended 30 June 2026, group revenue declined 6% to AUD 383.7 million from AUD 408.1 million. Gross profit was AUD 248.2 million and gross margin expanded to 64.7% from 60.6%. Branded products accounted for 83% of revenue, compared with 79% in FY25. Underlying EBITDA fell 27% to AUD 34.2 million amid higher Women’s Health spending and other cost pressures.

The annual report disclosed a profit from continuing operations after tax of AUD 31.2 million, compared with a loss of AUD 90.1 million a year earlier. After discontinued operations, the group recorded a net profit of AUD 24.5 million, versus a AUD 93.8 million loss in FY25. Adjusted operating cash flow from continuing operations was AUD 34.5 million, down AUD 10.9 million. Cash and marketable securities totalled AUD 80.0 million at year-end.

Product demand was uneven across the portfolio. US NEXTSTELLIS demand cycles increased 15% during FY26, BIJUVA prescriptions rose 26% and IMVEXXY prescriptions increased 6%. In the International division, revenue declined 7% as the company shifted its product mix and spent more on commercial activity in Australia. The pharmaceutical sector remains exposed to reimbursement policies, generics, patent disputes and regulator-mandated studies, all of which can affect commercial returns.

Risks to Consider

Mayne Pharma’s results remain sensitive to US product sales, the cost of supporting branded medicines and changes in insurer coverage. The annual report identified potential insurance coverage changes for TWYNEO and generic competition for RHOFADE. Regulatory and post-approval obligations can generate additional costs. Expansion of direct prescription fulfilment also introduces operational execution requirements, while litigation can absorb cash and management resources.

What to Watch Next

FY27 reporting will show whether DistributeRx prescription activity translates into segment earnings and cash generation. Other measurable milestones include the planned Kentucky fulfilment expansion, manufacturing utilisation at Salisbury and commercial performance of the Women’s Health portfolio. Investors may also monitor patent-related disclosures, the progress of Cosette proceedings and any revisions to financial guidance.

Key Insights

Mayne Pharma reported lower FY26 revenue and underlying EBITDA alongside improved gross margin and a return to statutory profit. Its priorities now include scaling direct distribution, managing product-level competition and resolving legal matters. Cash conversion, commercial execution and subsequent regulatory updates will be useful measures of progress.